https://www.selleckchem.com/products/ars-853.html
Future work is needed to examine the longitudinal outcomes of these subgroups to inform prevention and treatment.Melanoma can be classified based on the detection of relevant oncogenic driver mutations. These mutations partially determine a patient's treatment options. MEK inhibitors have demonstrated little efficacy in patients with NRAS-mutated melanoma owing to primary and secondary resistance. We report two patients with NRAS-mutant metastatic melanoma with long-term response to intermittent MEK-inhibitor binimetinib therapy. Interm
Like
Comment
Share
